Alan H. Wells,Cecelia C. Yates-Binder,Joel S. Schuman
申请号：
US14878370
公开号：
US09452200B2
申请日:
2015.10.08
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-γ-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
